Prognostic value of systemic immune-inflammation index in patients with gastric cancer treated with immune checkpoint inhibitors

Table 4 Receiver operating characteristic analysis of the risk factors for progressive disease within six months in gastric cancer patients receiving immune checkpoint inhibitors

Parameters	Best threshold	Sensitivities	Specificities	Area under the curve	Youden index	F1 score
Eastern Cooperative Oncology Group (2)	0.500	0.263	0.909	0.590	0.172	0.376
Clinical staging (IV)	0.500	0.832	0.364	0.598	0.196	0.596
Number of distant metastases (≥ 2)	0.500	0.621	0.573	0.597	0.194	0.549
Treatment regimen (combination therapy)	0.500	0.611	0.580	0.595	0.191	0.344
Programmed cell death ligand 1 overexpression (combined positive score ≥ 1)	0.500	0.747	0.441	0.594	0.188	0.577
Systemic immune-inflammation index	593.995	0.705	0.727	0.788	0.432	0.667